Clinical Trial Update: An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis [Phase 3]

View source ↗

Summary

Extension study of ublituximab in relapsing multiple sclerosis is a Phase 3 trial that is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Ublituximab (ublituximab)

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Relapsing Multiple Sclerosis (RMS) | Phase 3 | Status: ACTIVE_NOT_RECRUITING